Monoclonal Antibodies for Lipid Management

Matthew J. Feinstein, Donald M. Lloyd-Jones*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


In recent years, biochemical and genetic studies have identified proprotein convertase subtilisin/kexin type 9 (PCSK9) as a major mediator of low-density lipoprotein cholesterol (LDL-c) levels and thereby a potential novel target for reducing risk of coronary heart disease (CHD). These observations led to the development of PCSK9 inhibitors, which lower LDL-c levels more than any other non-invasive lipid-lowering therapy presently available. The PCSK9 inhibitors furthest along in clinical trials are subcutaneously injected monoclonal antibodies. These PCSK9 inhibitors have demonstrated LDL-c-lowering efficacy with acceptable safety in phase III clinical trials and may offer a useful therapy in addition to maximally tolerated HMG-CoA reductase inhibitors (statins) in certain patient groups. Longer-term data are required to ensure sustained efficacy and safety of this new class of medications. This review provides an overview of the biology, genetics, development, and clinical trials of monoclonal antibodies designed to inhibit PCSK9.

Original languageEnglish (US)
Article number39
JournalCurrent atherosclerosis reports
Issue number7
StatePublished - Jul 1 2016


  • Cholesterol
  • Coronary heart disease
  • LDL cholesterol
  • PCSK9
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Monoclonal Antibodies for Lipid Management'. Together they form a unique fingerprint.

Cite this